Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xtant Medical Holdings, Inc.XTNT · Entity 7196 | Chief Executive Officer | August 15, 2018 | August 16, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xtant Medical Holdings, Inc.
Report date August 15, 2018 · Filed August 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.20 · Expires 2028-08-15 | Direct | 200,000 |
Reported balance
After 2018-08-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-15 · Grant · Acquired 200,000 · Balance 200,000 F1: This option vests with respect to 50,000 shares on each of August 15, 2019, August 15, 2020, August 15, 2021 and August 15, 2022, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc. |
| Common Stock, $0.000001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2018-08-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests with respect to 50,000 shares on each of August 15, 2019, August 15, 2020, August 15, 2021 and August 15, 2022, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2018 Filed Aug 16, 2018 21:01 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001235802-18-000123 · primary_doc.xml · derivative · entry 2 O'Connell Carl · CIK 0001568971 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-08-15 F1 · derivative.exercise_date: This option vests with respect to 50,000 shares on each of August 15, 2019, August 15, 2020, August 15, 2021 and August 15, 2022, subject to such Reporting Person's continued employment with Xtant Medical Holdings, Inc. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 21:49 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | GrantStock Option · Derivative | 300,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001144204-16-127723 · v450396_4.xml · derivative · entry 1 O'Connell Carl · CIK 0001568971 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-10-06 F1 · derivative.exercise_date: The option vests as follows: 60,000 shares on October 6, 2017, and 15,000 shares each on January 6, 2018, April 6, 2018, July 6, 2018, October 6, 2018, January 6, 2019, April 6, 2019, July 6, 2019, October 6, 2019, January 6, 2020, April 6, 2020, July 6, 2020, October 6, 2020, January 6, 2021, April 6, 2021, July 6, 2021, and October 6, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.